Last Update 09 Mar 26

Fair value Increased 0.85%

KVUE: Future Returns Will Balance Legal Risks And Kimberly Clark Deal Execution

Analysts have nudged their fair value estimate for Kenvue to $19.83 from $19.67, reflecting recent price target increases into the $18 to $20 range after what they describe as a better than feared Q4 with broad-based segment growth.

Analyst Commentary

Recent Street research on Kenvue highlights a mix of cautious optimism and lingering concerns, with several firms lifting price targets into the high teens after reviewing Q4 results and updated models.

Bullish Takeaways

Bullish analysts point to Q4 as better than feared, which they see as supportive of Kenvue's current valuation range around the high teens.
Reports of a beat on both revenue and earnings in Q4 suggest, for these analysts, that execution landed ahead of their expectations, especially coming off recent quarters.
The first period since Q2 2023 where all three business segments showed year over year growth, helped by FX, is viewed as a sign that the broader portfolio is contributing to overall growth rather than relying on a single category.
Price targets clustered at US$18 to US$20 indicate that bullish analysts see some support for incremental upside if the company can sustain recent operating trends.

Bearish Takeaways

Bearish analysts, including Jefferies, are more cautious, as shown by their downgrade around the time of an announced deal getting closer to completion. They appear to view this as adding execution or integration risk.
The presence of Hold and Neutral ratings, even as price targets move higher, suggests some analysts see limited room for a major re-rating without clearer evidence of durable growth across segments.
FX benefits supporting year over year growth in Q4 are seen by cautious analysts as less controllable. This may make some of the recent strength harder to rely on if currency trends reverse.
The mix of raised targets alongside a downgrade underlines that investors are still weighing Q4 outperformance against questions on how consistent that performance will be over future quarters.

What's in the News

A Texas judge rejected Kenvue's request to dismiss a lawsuit from the state Attorney General alleging Tylenol was falsely marketed regarding autism and other risks to children when used by pregnant women, with the court's detailed reasoning not yet public (Reuters).
A Baltimore jury ordered Johnson & Johnson and its subsidiaries, including spinoff Kenvue, to pay more than US$1.5b in a talc case tied to asbestos exposure, finding them liable for failing to warn the plaintiff about alleged asbestos in baby powder products (Reuters).
Market chatter around Kenvue surfaced in Ben Harrington's M&A focused Betaville blog, with contacts citing a rumor related to the company (The Fly / Betaville blog).
Kenvue shareholders and Kimberly Clark shareholders voted to approve all proposals required for Kimberly Clark to acquire Kenvue, with closing targeted for the second half of 2026, subject to regulatory approvals and other customary conditions.
Chief Financial Officer Amit Banati notified Kenvue that he plans to step down in May 2026 to become chief executive officer at another company. Kenvue plans to appoint an interim principal financial officer ahead of the Kimberly Clark transaction closing.

Valuation Changes

Fair Value: increased slightly from $19.67 to $19.83 per share, a change of about 0.8%.
Discount Rate: adjusted down slightly from 7.79% to 7.52%, indicating a modest change in the required return used in the model.
Revenue Growth: revised fractionally lower from 2.92% to 2.89%, leaving the longer term growth assumption effectively unchanged.
Net Profit Margin: moved marginally higher from 12.94% to 12.96%, reflecting a very small tweak to expected profitability.
Future P/E: inched up from 22.01x to 22.03x, suggesting only a minimal change in the valuation multiple applied to future earnings.

4 views

Key Takeaways

Enhanced digital capabilities and operational streamlining are expected to boost market share, cost efficiency, and margins while supporting continued revenue growth.
Focus on innovation and emerging markets positions the company for sustained demand, premium pricing, and long-term expansion beyond mature regions.
Operational complexity, lagging e-commerce adaptation, internal leadership turbulence, macroeconomic pressures, and slow innovation expose Kenvue to ongoing margin contraction and long-term competitive risks.

Catalysts

About Kenvue

Operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America.What are the underlying business or industry changes driving this perspective?

New leadership with strong digital and data expertise, combined with targeted investments in e-commerce and AI, positions Kenvue to capitalize on rising consumer adoption of digital health retail channels-this shift should drive higher volume growth, improved market share, and eventually support topline revenue acceleration.
Strategic focus on streamlining operations, including reducing internal complexity and concentrating resources on best-selling brands and key regions, is expected to unlock cost efficiencies, improve decision-making speed, and enhance net margins and earnings over time.
Accelerated innovation pipeline and shift toward consumer-centric product development (e.g., premium, natural, and dye-free options in Tylenol and oral health) aligns the portfolio with sustained demand for preventative health and wellness products, supporting resilience in core revenues and higher average selling prices.
Modernization and further digitization of the supply chain, as well as procurement and network optimization, should reduce supply chain costs and working capital needs, resulting in better cash flow conversion and expansion in gross margins.
Expansion and brand-building in emerging markets (LatAm and EMEA showing early gains), alongside leveraging the growing middle class and increasing disposable incomes in these areas, offers long-term revenue and earnings growth potential as these markets outpace mature geographies.

Kenvue Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Kenvue's revenue will grow by 2.6% annually over the next 3 years.
Analysts assume that profit margins will increase from 9.4% today to 13.1% in 3 years time.
Analysts expect earnings to reach $2.1 billion (and earnings per share of $1.11) by about September 2028, up from $1.4 billion today. The analysts are largely in agreement about this estimate.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 25.8x on those 2028 earnings, up from 25.5x today. This future PE is greater than the current PE for the US Personal Products industry at 22.8x.
Analysts expect the number of shares outstanding to grow by 0.09% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 8.23%, as per the Simply Wall St company report.

Kenvue Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Kenvue's self-described significant complexity across SKUs, brands, and geographies has led to operational inefficiencies and underperformance, and addressing this complexity (through possible SKU/country/brand reductions or divestitures) could create short
to medium-term revenue and volume headwinds, with slow turnover to improved profitability in the long-term.
Kenvue is underdeveloped in e-commerce versus brick-and-mortar, an area where industry trends and consumer buying are rapidly shifting; failure to pivot quickly or effectively risks ongoing volume and market share losses, pressuring both revenue and net margins relative to more digitally agile competitors.
Ongoing strategic review, leadership turnover, and not delivering on our growth potential statements from management signal internal uncertainty and transition risk, which may result in further disruption, restructuring costs, and unreliable earnings or margins during execution of any transformative plans.
Macroeconomic headwinds (e.g., softening categories, muted consumer sentiment, retailer inventory destocking), as well as persistent inflation and tariffs not fully offset by productivity initiatives, are expected to cause margin contraction and lower net earnings-management even revised guidance to reflect declining organic sales and shrinking operating margin.
While brands like Tylenol show strong performance, Kenvue's slow innovation velocity, heavy reliance on mature legacy brands, and delayed response to competitive shifts in mild, clean, and natural personal care segments (e.g., Listerine's weakness in alcohol-free) suggest long-term risks to revenue growth and profit margin due to changing consumer preferences and new disruptive entrants.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $22.6 for Kenvue based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $26.0, and the most bearish reporting a price target of just $19.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $16.3 billion, earnings will come to $2.1 billion, and it would be trading on a PE ratio of 25.8x, assuming you use a discount rate of 8.2%.
Given the current share price of $18.87, the analyst price target of $22.6 is 16.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Kenvue?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Analyst Commentary Highlights Legal Risks and Valuation Adjustments for Kenvue Amid Market Uncertainty